IDEA AG - US Patent Office grants a new patent - Gilde Healthcare

IDEA AG – US Patent Office grants a new patent

5. Februar 2009

Munich, Germany – IDEA AG today announced the granting of a new US patent (7,473,432) that covers the recently improved Transfersome® technology and the Company’s lead product, Diractin®, which is already approved in Switzerland and in the final stage (phase III) of clinical development in Europe and the USA.

The invention describes and claims new formulations of non-steroidal anti-inflammatory drugs (NSAIDs) based on complex aggregates, the Transfersome® vesicles, with at least three amphiphatic components suspended in a suitable polar liquid.  The key characteristic of the aggregates is their ability to penetrate narrow hydrophilic pores in a semi-permeable barrier, such as the skin. This enables the Transfersome® carriers to transport NSAIDs through the skin barrier for improved local deposition and longer duration of drug action. The newly patented NSAID carriers moreover help to control the depth of drug delivery, by virtue of their special ability to bypass the sink of cutaneous blood capillaries. The carrier-mediated localized delivery of NSAIDs can consequently ameliorate therapy of diseased peripheral tissues below the site of administration, by supporting the beneficial action and minimizing the systemic side effects of such drugs.

The new patent also specifically covers Diractin® (ketoprofen in Transfersome® gel, formerly known as IDEA-033). It thus provides a valuable basis for future marketing of IDEA’s innovative targeted analgesic in the United States. In September 2007 IDEA has out-licensed the US right to a subsidiary of Alpharma Inc., which was recently acquired by King Pharmaceuticals Inc. The IP protection under this newly granted patent will last till June 2025.

Gilde Healthcare Portfolio Company Big Health Adds Former FDA Deputy Commissioner Anand Shah to Its Board of Directors

Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced that it has added former Food and Drug Administration (FDA) Deputy Commissioner for Medical and Scientific Affairs Dr....
26. Januar 2022

Gilde Healthcare Portfolio Company Big Health Raises $75 Million in Series C Funding

Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced that it has raised $75 million in a Series C funding round, led by new investor SoftBank Vision...
19. Januar 2022

ProVerum raises €30M in Series A funding led by Gilde Healthcare & Lightstone Ventures

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor’s office, today announced the closing of a €30 million Series A equity financing led...
11. Januar 2022